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Background: Individuals with nonfunctional transporter associated with antigen processing (TAP) present ligands gener-
ated by TAP-independent processing pathways associated with classical HLA class I molecules.
Results: A vaccinia virus ligand is efficiently presented by nonclassical HLA-E using alternative interactions.
Conclusion: Nonclassical HLA-E presents viral ligands.
Significance: This expands the role of HLA-E as an antigen-presenting molecule.
The transporter associated with antigen processing (TAP)
enables the flow of viral peptides generated in the cytosol by the
proteasome and other proteases to the endoplasmic reticulum,
where they complex with nascent human leukocyte antigen
(HLA) class I. Later, these peptide-HLA class I complexes can be
recognized by CD8 lymphocytes. Cancerous cells and infected
cells in which TAP is blocked, as well as individuals with unus-
able TAP complexes, are able to present peptides onHLA class I
by generating them throughTAP-independent processingpath-
ways. Here, we identify a physiologically processed HLA-E
ligand derived from the D8L protein in TAP-deficient vaccinia
virus-infected cells. This natural high affinity HLA-E class I
ligand uses alternative interactions to the anchor motifs previ-
ously described to be presented onnonclassicalHLAclass Imol-
ecules. This octameric peptide was also presented on HLA-Cw1
with similar binding affinity on both classical and nonclassical
class I molecules. In addition, this viral peptide inhibits HLA-E-
mediated cytolysis by natural killer cells. Comparison between
the amino acid sequences of the presenting HLA-E and HLA-
Cw1 alleles revealed a shared structural motif in bothHLA class
molecules, which could be related to their observed similar
cross-reactivity affinities. Thismotif consists of several residues
located on the floor of the peptide-binding site. These data
expand the role of HLA-E as an antigen-presenting molecule.
CD8 cytolyticT lymphocyte-mediated recognition and kill-
ing of virally infected cells first requires proteolytic degradation
of viral proteins by the proteasome and other cytosolic pro-
teases (1). This degradation generates short peptides of 8–11
amino acids, which are then translocated to the endoplasmic
reticulum lumen by transporter associated with antigen proc-
essing (TAP),2 where they assemble with newly synthesized
HLA class I heavy chain and 2-microglobulin.
Humans and mice with mutations in the TAP gene that gen-
erate nonfunctional TAP complexes have been described (2, 3).
This TAP deficiency implies reduced functionality of the CD8
population, but TAP-deficient patients are not particularly sus-
ceptible to viral infections or neoplasms. Thus, TAP-indepen-
dent HLA class I loading pathways may be sufficient to control
these diseases and allow these individuals to live with only a
increased susceptibility to chronic respiratory bacterial infec-
tions. In addition, several strains of viruses have specific mech-
anisms to block TAP expression or to prevent CD8 lympho-
cytes from identifying infected cells (reviewed in Ref. 4);
therefore, the TAP-independent pathways must also be impor-
tant for killing cells infected with these viruses.
Early administration of the cowpox virus, which encodes for
a TAP-blocking protein (5), was the inspiration for the massive
worldwide cross-protective vaccination by vaccinia virus
(VACV) that eradicated pandemic smallpox, a disease caused
by the variola major virus (6). The Orthopoxvirus vaccinia is a
widely used tool for research and vaccine development (7). Cur-
rently, bioterrorism and emerging infectious diseases have elic-
ited renewed interest inVACVand other poxviruses (8). VACV
administration generates a strong humoral response leading to
viral clearance, and the role of cytotoxic T lymphocyte
responses in this cross-protection is well documented (9, 10).
During the last several years, studies in both HLA-transgenic
mouse models and vaccinated humans have identified more
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than 70 VACV-derived epitopes presented by various HLA
molecules (11, 12).
HLA-E is a nonclassical class I molecule that binds mono-
morphic signal peptides derived from classical HLA class I pro-
teins. This complex is the ligand of innate receptors expressed
mainly by natural killer cells and thereby regulates lymphocyte
activity (13). Several recent studies have indicated that HLA-E
complexed with pathogen-derived peptides could be recog-
nized by CD8 T cells (14). In addition, binding to HLA-E has
been demonstrated for some viral peptides that were previously
thought to bind the classical HLA-A2 class I molecule (15, 16).
In a previous study usingmass spectrometry to analyzeHLA-
bound peptide pools isolated from large numbers of TAP-defi-
cient VACV-infected cells, we identified eleven ligands that
were naturally presented by four different HLA-A, -B, and -C
class I molecules (17). Of these, six were obtained by immuno-
precipitation with the mAb W6/32, which is specific for a
monomorphic HLA class I determinant (18). Later, to identify
theHLA restriction of these ligands,HLA-peptide complex sta-
bility assays were performed using the TAP-deficient T2 cells
with specific anti-HLAmAbs (17). Two of these VACV ligands
were endogenously presented by HLA-B51 in human TAP-de-
ficient cells, and another three were presented by HLA-Cw1
class I molecules. In addition, one VACV ligand, C11R101–110,
was presented by both classical HLA-B51 and -Cw1 class Imol-
ecules in infected cells. Because the mAb W6/32 used in the
HLA immunoprecipitation recognizes a conformational
epitope on human HLA class I molecules, including the non-
classical HLA-E allele (19), some of these six VACV ligands
could also have additional binding ability and could be pre-
sented by theHLA-E allele inT2TAP-deficientVACV-infected
cells. In the present study, we explore a possible role for HLA-E
in presenting some of the previously described TAP-indepen-
dent VACV ligands.
EXPERIMENTAL PROCEDURES
Cell Lines—T2 cells are a line of TAP-deficient human cells
that expressHLA-A2, -B51, and -Cw1 class Imolecules on their
surface (20). The 721.221 cells are a HLA-A, -B, and -C null
human line that express HLA-E on their surface (21). Both cell
lines were cultured in RPMI 1640 supplemented with 10%
fetal bovine serum and 5 M -mercaptoethanol. The NK3.3
natural killer cells were cultured in -minimal essential
medium supplemented with 100 units/ml recombinant human
IL-2 and 25% FBS (22). Recombinant human IL-2 was gener-
ously provided by Hoffmann-La Roche for the long term prop-
agation of NK3.3 cell line.
Synthetic Peptides—Peptideswere synthesizedwith a peptide
synthesizer (model 433A; Applied Biosystems, Foster City, CA)
and were purified by reverse phase HPLC. The monosubsti-
tuted Ala analogues of VACV D8L peptide (DGLIIISI) were
named according to the position of the substituted residue.
Thus, A3 refers to the octamer of sequence DGAIIISI. The cor-
rectmolecularmass of the peptideswas established byMALDI-
TOF MS, and their correct composition was determined by
MS/MS on a quadrupole ion trap micro-HPLC.
HLA-Peptide Stability Assays—The following synthetic pep-
tides were used as controls in HLA-peptide complex stability
assays: KPNA2 (GLVPFLVSV, HLA-A2-restricted) (23), HBV
HBc19–27 (LPSDFFPSV, HLA-B51-restricted) (24), CMV
pp657–15 (RCPEMISVL, HLA-Cw1-restricted) (25), the leader
peptide of HLA (VMAPRALLL, HLA-E-restricted), and
C4CON (QYDDAVYLK, HLA-Cw4-restricted) (26).
The T2 line of TAP-deficient cells expresses low amounts of
classical MHC class I on the cell surface. For classical HLA-A2,
-B51, and -Cw1 class I stability assays, T2 cells were incubated
at 26 °C for 16 h in RPMI 1640medium supplementedwith 10%
heat-inactivated FBS. This allows the expression of empty
MHC class I molecules that lack antigenic peptide and are only
stable on the cell membrane at 26 °C and not at 37 °C. Later, the
cells were washed and incubated for 2 h at 26 °C with various
concentrations of peptide in the same medium. The cells were
then kept at 37 °C and collected for flow cytometry after 4 h
(27). This assay allows for the internalization of empty HLA
class I molecules and can therefore discriminate between
bound and unbound peptides.
ForHLA-E stability assays, T2 cells were incubatedwith pep-
tides for 6 h at 37 °C in culturemedium before immunofluores-
cent staining as described previously (15). This treatment
enhances cell surface expression of HLA-E class I molecules
bearing specific HLA-E-bound peptides (15).
HLA expression levels were measured using the following
Abs: monoclonal 3D12 (anti-HLA-E) (28), monoclonal PA2.1
(anti-HLA-A2) (29), polyclonal H00003106-B01P (specific for
HLA-B class I molecules) (Abnova, Taipei, Taiwan), and poly-
clonal SC-19438 (specific for HLA-C class I molecules) (Santa
Cruz Biotechnology, Santa Cruz, CA) as previously described
(30). The samples were assayed on a FACSCanto flow cytome-
ter (BD Biosciences) and analyzed using CellQuest Pro 2.0 soft-
ware (BD Bioscience). The cells incubated without peptide had
peak fluorescence intensities similar to the background staining
observed with the secondary Ab alone or isotypic controls. The
fluorescence indexwas calculated as the ratio of themean chan-
nel fluorescence of the sample to that of control cells incubated
without the peptides. Peptide binding was also expressed as
EC50, which is defined as the molar concentration of the pep-
tides producing 50% of the maximum fluorescence obtained at
a concentration range between 0.001 and 100 M.
T Cell Line and Cytotoxicity Assays—Cytotoxicity assays
were performed using the 721.221 cell line as target (T) cells
and NK3.3 cell line as effector (E) cells. Before performing the
assay 1  105 target cells were incubated overnight at 26 °C
either in the absence or in the presence of the indicated pep-
tides at 100 M. A 2-h 51Cr release assay was performed as
previously described (21). Specific lysis was calculated as
[(experimental release  spontaneous release)/(maximum
release  spontaneous release)]  100. The spontaneous
release never exceeded 20%.
Statistical Analysis—To analyze statistical significance, an
unpaired Student t test was used. p values 0.001 were consid-
ered to be significant.
Molecular Dynamics: Starting Structures—The native leader
peptide HLA-E-binding peptide was taken from chains A, B,
and C of the 3bzf Protein Data Bank file. The D8L112–119 pep-
tide bound toHLA-Emodel was built with theMODELLER9v7
program using the 3bzf Protein Data Bank file as template. The
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protonation states of the ionizable groups for the three system
were calculated using the H server (31) (32). The positions
of hydrogen atoms, standard atomic charges, and radii for all
the atoms were assigned according to the ff03 force field (33).
The complexes were immersed in cubic boxes of TIP3P water
molecules that were large enough to guarantee that the shortest
distance between the solute and the edge of the box was more
than 13 Å (34). Counter ions were also added to maintain elec-
troneutrality. Three consecutive minimizations were per-
formed: the first involved only hydrogen atoms, the second
involved only the water molecules and ions, and the third
involved the entire system.
Simulation Details—The initial minimized structures, pre-
pared as stated before, were simulated in the NPT ensemble
using Periodic Boundary Conditions and Particle Mesh Ewald
to treat long range electrostatic interactions. The systems were
then heated and equilibrated in two steps. The first step
involved 200 ps of MD heating the whole system from 100 to
300 K, and the second involved equilibration of the entire sys-
temduring 1.0 ns at 300K. The equilibrated structures were the
starting points for the 10-ns MD simulations at constant tem-
perature (300 K) and pressure (1 atm). The SHAKE algorithm
was used to keep bonds involving hydrogen atoms at their equi-
librium length, allowing a 2-fs time step for the integration of
Newton’s equations of motion. ff03 and TIP3P force fields, as
implemented in AMBER 10 package, were used to describe the
proteins, the peptides, and the water molecules, respectively.
Sample frames at 20-ps intervals from the molecular dynamics
trajectory were subsequently used for analysis.
Interaction Energies Analysis—Effective binding free ener-
gies between the peptides and HLA-E were estimated using the
MM-GB-SA approach as implemented in the AMBER10 pack-
age (35). The MM-GB-SA method approaches the free energy
of binding as a sum of amolecularmechanics (MM) interaction
term, a solvation contribution thorough a generalized Born
(GB)model, and a surface area (SA) contribution to account for
the nonpolar part of solvation. In addition, to better character-
ize peptide-protein interactions, an energy decomposition
analysis in a pairwise fashion (between the peptides residues
and HLA-E residues) was performed using a cutoff of 5 Å from
the peptides. Polar contribution to solvation free energies were
calculated with GB, whereas nonpolar were estimated to be
proportional to the area lost upon binding using the linear com-
binations of pairwise overlaps (LCPO) method to calculate
accessible surface areas (36). These calculations were per-
formed for each snapshot from the simulations using the
appropriate module within AMBER 10 package.
RESULTS
VACV D8L112–119 Is a Noncanonical HLA-E Ligand—To
explore the potential role of HLA-E as an antigen-presenting
molecule of TAP-independent VACV ligands, HLA-peptide
complex stability assays were performed using TAP-deficient
T2 cells with an anti-HLA-E Ab. Fig. 1 shows that in contrast
with a control HLA-E ligand, the leader peptide of HLA, the
induction of complexes with five of the six VACV peptides
tested were not detected. Thus, these viral ligands do not bind
to HLA-E. In contrast, the D8L112–119 synthetic peptide
induced similar numbers of HLA-peptide surface complexes as
the positive control HLA-E ligand (Fig. 1). The consensus pep-
tide-binding motif for HLA-E is Met, Leu, or Gln at peptide
position 2 (P2); Leu, Ile, Val, or Pro at P7; and Leu, Glu, or Phe
C-terminal residues (37, 38). Thus, the D8L112–119 octamer
DGLIIISI is an unusual VACV ligand presented byHLA-E class
I molecules.
Identical Binding Affinity to Classical HLA-Cw1 and Non-
classical HLA-E Class I Molecules for the Viral D8L112–119
Peptide—TheD8L112–119 peptide was previously described as a
HLA-Cw1-restricted ligand (17). Because the mAb 3D12 used
in the current study for HLA-E binding cross-reacts with some
HLA-C class I molecules, although not with HLA-Cw1 (39),
HLA-peptide complex stability assayswere performedusingT2
cells incubated with a natural high affinity HLA-Cw1 ligand,
the CMV pp65 peptide (25), and stained with the anti-HLA-E
mAb 3D12 to exclude HLA-Cw1 cross-reactivity. In this case,
induction of HLA complexes with the CMV pp65 peptide was
not detected (data not shown). Thus, the mAb 3D12 does not
bind to HLA-Cw1.
In addition, the relative affinity of D8L112–119 to both HLA-E
and -Cw1 class I molecules was evaluated. This peptide bound
to HLA class I molecules in the range commonly found among
natural ligands (Fig. 2). This octamer efficiently stabilized












FIGURE 1. HLA-E stabilization with synthetic VACV ligands. The stability of
HLA-E-peptide complexes on the cell surface of T2 TAP-deficient cells was
measured by flow cytometry. The indicated peptides were used at 200 M.
The KPNA2 peptide and the leader peptide of HLA were used as negative and
positive controls, respectively. The mAb 3D12 was used for staining. The
results, calculated as fluorescence index values  S.D., are the means of four
to five independent experiments. ***, significant p values (p  0.001). A rep-
resentative experiment was depicted in the bottom panel. Shaded histogram,
isotypic control; thin line, KPNA2 peptide; medium line, D8L 112–119; thick line,
leader peptide of HLA.
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HLA-E (Fig. 2, left panel) and HLA-Cw1 (Fig. 2, right panel)
expression on cells, with an EC50 for MHC binding of 14  3
and 18  7 M, respectively, confirming their dual presenta-
tion. These EC50 values are similar to those of the other natural
high affinity ligands used as positive controls. In summary, the
VACV D8L112–119 octamer is a TAP-independent high affinity
ligand presented by both classical and nonclassical class I
molecules.
The D8L112–119 Peptide Is Not a HLA-A2 or -B51 Ligand—Some
viralHLA-E-binding ligandswere previously described asHLA-
A2-restricted epitopes (15, 16). In addition, HLA-A2 and -Cw1
class I molecules present some peptides with similar anchor
motifs (SYFPEITHI database (40)). Thus, HLA-peptide com-
plex stability assays were performed to study possible
HLA-A2 cross-reactivity of D8L112–119 ligand. Fig. 3 (upper
panel) shows that induction of HLA-A2 complexes with the
vaccinia D8L112–119 peptide was not detected, in contrast to a
control HLA-A2 ligand, the KPNA2 peptide. Thus, this viral
ligand does not bind to HLA-A2.
Because the HLA-B51 was also expressed in the T2 cell line,
and HLA-B51 and -Cw1 class I molecules present some pep-
tides with similar anchor motifs (SYFPEITHI database (40)),
the possible HLA-B51 cross-reactivity of D8L112–119 ligandwas
examined. HLA-peptide complex stability assays were per-
formed in which HLA-B51 molecules were stained in the pres-
ence of the VACV ligand. In contrast to a control HLA-B51
ligand, the HBV HBc peptide, induction of complexes with the
vaccinia D8L112–119 peptide was not detected (Fig. 3, lower
panel). In summary, this viral ligand binds to HLA-E and -Cw1
but not to HLA-A2 or -B51 alleles.
The Viral D8L112–119 Peptide Inhibits Cytolysis Mediated by
Natural Killer Cells—Because HLA-E/peptide-complexes are
recognized by different NK cell receptorsmediating either acti-
vating or inhibitory signals, we studied whether the binding of
D8L112–119 ligand to HLA-E alters cytolytic activity of natural
killer cells. Thus, 721.221 HLA-E cells were incubated with
the viral peptide, and a standard 51Cr release assay was per-
formed.As indicated in Fig. 4, incubation of target cells with the
D8L112–119 peptide reduced their susceptibility to NK3.3-me-
diated cytotoxicity (65  9% of specific inhibition) to a similar
extent as was obtained with the positive control peptide (71 
6% of specific inhibition), whereas incubation of 721.221 cells
with an irrelevant peptide had no effect on cytotoxic function of
NK3.3 cells.
VACVD8L112–119UsesAlternative Interactions to theAnchor
Motifs Previously Described for Its Presenting HLA-E Class I
Molecule—The crystal structure ofHLA-E, in complexwith the
peptide VMAPRALLL, has been previously described (41). In
contrast to classical HLA class I molecules, where the peptides
that bind different allotypes are anchored by two primary spec-
FIGURE 2. Binding affinity to HLA-E and -Cw1 of VACV D8L112–119 syn-
thetic peptide. The synthetic peptide VACV D8L112–119 (circles) was titrated
bound to HLA-E (left panel) or HLA-Cw1 (right panel) on T2 TAP-deficient cells,
and stabilization of HLA was measured by flow cytometry. The KPNA2 pep-
tide was used as a negative control (solid line). The leader peptide of HLA and
CMV pp657–15 were used as positive controls (squares) for binding to the
HLA-E and -Cw1 alleles, respectively. The Abs used were monoclonal 3D12
(anti-HLA-E, left panel), and polyclonal SC-19438 (anti-HLA-C class I molecules,
right panel). The data calculated as EC50 values  S.D. are shown below and
are the means of three to five independent experiments.
FIGURE 3. HLA-A2 and -B51 stabilization assay with synthetic VACV
D8L112–119 ligand. The stability of HLA-A2-peptide (upper panel) or HLA-B51-
peptide (lower panel) complexes on the surface of T2 TAP-deficient cells were
measured by flow cytometry. The indicated peptides were used at 200 M.
The KPNA2 and the HBV HBc peptides were used as positive controls for
binding to the HLA-A2 and -B51 alleles, respectively. The C4CON and the
KPNA2 peptides were used as negative controls for binding to the HLA-A2
and -B51 alleles, respectively. The Abs used were monoclonal PA2.1 (anti-
HLA-A2, upper panel) and polyclonal H00003106-B01P (anti-HLA-B class I mol-
ecules, lower panel). The results, calculated as in Fig. 1, are the mean of four
independent experiments. ***, significant p values (p  0.001).
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ificity pockets in the binding groove,HLA-Epossesses fivemain
anchor sites at the P2, P3, P6, P7, and P9 positions (Fig. 5A). The
pockets accommodating the side chains at the P2, P7, and P9
positions are deep, but those at the P3 and P6 positions are
relatively shallow. The A pocket interacts with the P1 Val resi-
due (Fig. 5A). The P2 and P3 side chains are directed into pock-
ets on opposite sides of the groove to the deep B and the shallow
D pockets. The superficial C pocket interacts with the P6 Ala
residue, and the P7 residue is accommodated into E pocket.
Last, the side chain of P9 is buried in the F pocket.
Modeling of the VACV D8L112–119 octamer peptide in com-
plex with HLA-E was based on the existing x-ray structure of
the VMAPRALLL-HLA-E complex (Fig. 5). Two alternative
conformations with similar HLA-E interaction energies were
predicted. The first (A model) keeps the interaction of P1
N-terminal residuewith theA pocket but loses contact with the
C residue with the F pocket (Fig. 5B). In contrast, in the sec-
ond conformation (B model), the lateral chain of the N-termi-
nal P1 residue is buried in the B pocket, and contacts between
the side chain of P8 and the F pocket are conserved (Fig. 5C).
The P6 residue is an anchor residue in both alternative confor-
mations, although it interacts with different pockets: the C
pocket in the Amodel (Fig. 5B) and the E pocket in the Bmodel
(Fig. 5C). These different models predicted mutually exclu-
sive interactions with either the P3 residue and the D pocket
(A model; Fig. 5B) or the P5 residue and the C pocket (B
model; Fig. 5C).
To test the two alternative models, new HLA-peptide com-
plex stability assayswere performedusingmonosubstitutedAla
analogues of D8L112–119 peptide. Substituting Ala with the P6
Ile residue, which could serve as anchor motif in either of the
two conformations, abolished interactions between the HLA
and the viral octamer (Fig. 6). Additionally, substituting the P3
Leu with Ala abrogated peptide binding to HLA-E molecule,
suggesting that this residue serves as an anchor motif as it does
in theAmodel (Fig. 5B). In contrast, exchangingAlawith either
P5 Ile or P8 Ile residues, which could be additional anchor res-
idues forHLAmolecule in the Bmodel but were absent in theA
model as suggested by the modeling of Fig. 5 (B and C), had no
effect on the stabilization of HLA-E molecules (Fig. 6). In sum-
mary, the analysis of HLA-D8L112–119 interactions using
monosubstitutedAla analogues indicated that this viral peptide
bound toHLA-E using only the two anchor residues P3 Leu and
P6 Ile, consistent with the A model but not consistent with the
B model.
DISCUSSION
The results reported here show that the 112–119 octamer
derived from the vaccinia D8L protein is efficiently presented
by the MHC class I molecule HLA-E using alternative interac-
tions with the anchor motifs previously described for this non-
classical MHC class I molecule. In addition to the its role in the
presentation of monomorphic signal peptides derived from the
classical HLA class I proteins to the innate receptors (13),
HLA-E was identified as a restriction element for bacteria (42,
FIGURE 4. VACV D8L112–119 synthetic peptide inhibits HLA-E-mediated
cytotoxicity by natural killer cells. 721.221 target cells prepulsed with 100
M of the indicated synthetic peptides were tested in a standard cytolytic
assay for natural killer cytotoxicity with NK3.3 cells. The leader peptide of HLA
(squares) and an irrelevant peptide (diamonds) were used as positive and
negative controls, respectively. The data are the means of three independent
experiments  S.D. ***, significant p values (p  0.001) were found between
no peptide or irrelevant peptide versus leader peptide of HLA or D8L112–119.
FIGURE 5. Modeling of HLA-E-bound conformations of VACV D8L112–119
peptide. The backbone atoms of the indicated HLA-E-bound peptides are
displayed as ribbon tubes (A, VMAPRALLL; B and C, DGLIIISI in two possible
conformations: A model and B model, respectively). The atoms are repre-
sented by sticks using the following color scheme: blue, nitrogen; red, oxygen;
and green, carbon. The peptide residues that interact with the indicated
HLA-E pockets are designated. The HLA-E protein is not displayed. The figure
was prepared using the PyMOL program.
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43) and some viral peptides fromEBV (15), HCV (16), HIV (44),
and influenza (15). Moreover, most of these viral, but not bac-
terial, peptides are capable of binding to both classical HLA-A2
and nonclassical HLA-E class I molecules (15, 16), suggesting
that HLA-E may bind, at least in part, a repertoire of viral
pathogen antigens comparable with HLA-A2 despite the large
sequence differences found. Comparison between the HLA-E
and HLA-A2 sequences shows 42 amino acid differences in
residues located in the peptide binding groove,with 15 conserv-
ative and 27 nonconservative changes (Table 1). In our study,
the vaccinia ligand showed HLA cross-reactivity with HLA-
Cw1 but not HLA-A2 class I molecules. Sequence analysis
betweenHLA-E andHLA-Cw1 class Imolecules reveals a lower
degree of differences thanHLA-A2with 14 conservative and 20
nonconservative amino acid changes in the residues facing the
antigen-binding site (Table 1). Fourteen residues are identical
in HLA-E andHLA-Cw1 and are not conserved in the HLA-A2
sequence, but only six of them are facing the peptide binding
groove: three in the  sheets (Ser-24, Leu-95, and Trp-97) and
three in the  helix (Arg-62, Ala-71, and Glu-152) (Fig. 7).
When similar sequence analysis betweenHLA-E andHLA-B51,
which did not cross-react with the D8L viral ligand, was carried
out, only four residues located in the peptide binding groove
(Ser-24, Ala-71, Leu-95, and Trp-97) were observed to be iden-
tical, but they were not conserved in the HLA-A2 or -B51 class
Imolecules (Table 1 and Fig. 7). All four of these residuesmatch
the minimum desetope conserved between HLA-E and HLA-
Cw1 but absent in HLA-A2 or -B51 and thus are possibly
responsible for the cross-reactivity of the D8L112–119 ligand. In
addition, althoughHLA-A2, -B51, and -Cw1 present some pep-
tides with similar P2 and P anchor motifs, overlapping pep-
tide repertoires are not described (SYFPEITHI database (40)).
Thus, the cross-reactivity identified in the current report
FIGURE 6. HLA stabilization assay with monosubstituted Ala analogues
of VACV D8L112–119 synthetic peptide. Stability at the cell surface of HLA-E
on the cell surface of T2 TAP-deficient cells was measured by flow cytometry.
The indicated peptides were used at 200 M. The KPNA2 peptide was used as
negative control. The mAb 3D12 was used for staining. The data, calculated as
in Fig. 1, are the means of three or four independent experiments. ***, signif-
icant p values (p  0.001).
TABLE 1
Polymorphic residues among HLA class I molecules
a 1 and 2 HLA-E residues were compared with HLA-Cw1, -A2, or -B51 class I Molecules. Blanks indicate identity with the HLA-E-reference sequence. The identical resi-
dues identified between HLA-E and HLA-Cw1 but not HLA-A2 or -B51 molecules (minimum desetope) and proposed as contributing to a shared structural motif that
could confer peptide presenting similarities to HLA-E and HLA-Cw1 are in bold type. The sequences are from the IMGT/HLA Database.
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betweenHLA-E and -Cw1, an allele not clustered into HLA-A2
supertype, expands the range of possible HLA-E cross-reactiv-
ity and indicates that several other HLA class I viral ligands
different from HLA-A2-restricted epitopes could be presented
in association with HLA-E. Thus, future studies analyzing the
HLA-E peptide repertoire under infection conditions with dif-
ferent viruses are needed.
Some studies have shown cross-reactivity of epitopes
between very differentMHC class I molecules. Cross-reactivity
between multiple HLA-B alleles (HLA-B7, -B27, -B40, -B54,
-B55, and -B56) that differ by 20 residues facing the antigen-
binding site has been widely reported (45). Additionally, inter-
species cross-reactivity of viral ligands, shared by a human and
a rhesusmacaque, a rhesusmacaque and amouse, a human and
a mouse, and two different chimpanzeeMHC class I molecules
have been described (46–49). These pairs of cross-reactive
MHCmolecules are very different and havemarked differences
in the sequence and structure of the peptide-binding groove.
Dual reactivity of CD8 T cell clones reflected presentation of
structurally related peptides by two HLA class I and II mole-
cules: HLA-B27 and HLA-DR2 (50). These findings and the
results reported in the current study show the complexity and
plasticity of interactions in MHC-peptide complexes.
Our study includes one distinct difference from the previous
viral classical andnonclassicalHLAcross-reactivity reports (15,
16, 44); the D8L112–119 ligand was isolated from TAP-deficient
vaccinia virus-infected cells, and thus this viral ligand was nat-
urally processed by a TAP-independent pathway previous to its
presentation by HLA-E. Only the HCMV gpUL-40-derived
ligand is currently known to assemble with HLA-E via a TAP-
independentmechanism (51). This peptide exactlymatches the
leader sequence peptides of various HLA class I alleles and is
able to substitute for the natural leader peptides from HLA-E
produced by TAP that are blocked by the protein US6 in
HCMV-infected cells (52). Therefore, this TAP-independent
antigen presentation was previously reported as a viral mecha-
nism to bypass the normal HLA-E loading system that evolved
to occlude NK cell recognition of infected cells, whereas most
HCMVepitopes remain in the cytosolwithout any possibility of
entering the endoplasmic reticulum. Unlike this previously
described tolerogenic peptide, D8L112–119 could be recognized
by CD8 T cells in the same manner as vaccinia virus-encoded
HLA-A2-restricted epitopes generated in the same TAP-defi-
cient infected cells (17), allowing it to contribute to host defense
against viral infection. Lastly, the lack of polymorphism of the
HLA-E gene in humans suggests that D8L112–119 could be a
universal epitope, requiring future studies to understand the
HLA-E-restricted response of this viral peptide.
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